ABLi Therapeutics Launches with Novel Parkinson’s Therapy
Tuesday, May 13, 2025
ABLi Therapeutics (ABLi) has officially launched.
The company is dedicated to developing therapies that target conditions caused by the activation of Abelson Tyrosine Kinases (c-Abl kinases), with Parkinson’s disease and related disorders as its primary focus.
Risvodetinib has shown encouraging results in clinical studies. In a recent placebo-controlled trial (NCT05424276), it was the first monotherapy to improve quality of life in patients with untreated Parkinson’s disease while also demonstrating a reduction in disease-related pathology.
The treatment is taken orally once daily and has been designed to interfere with the mechanisms believed to drive disease progression. It is currently protected by intellectual property rights extending beyond 2036.
ABLi’s lead product candidate, risvodetinib (ABLi-148009), is being developed as a potential disease-modifying treatment. Unlike existing therapies that manage symptoms, risvodetinib aims to address the root causes of Parkinson’s disease.
The company has also established a portfolio of second-generation product candidates based on its proprietary RAMP™ drug development platform. This platform has produced a range of small-molecule inhibitors that are selective for non-receptor c-Abl kinases.
These new compounds are reported to offer improved potency and safety compared to current commercially available options and are capable of reaching therapeutic levels in both the brain and peripheral tissues.
ABLi is supported by a scientific advisory board comprising experts in Parkinson’s and related neurological conditions, guiding the company's efforts to bring innovative therapies to patients.
Source: globenewswire.com
